Keywords: ucb, keppra, forges, ahead, sales, up, net
UCB's Keppra forges ahead with sales up 35%; 2003 net profit rises 21% at CER
Article | 16 February 2004
Belgian pharmaceutical and chemicals group UCB reported estimated net profit after tax of 337 million euros ($418.4 million) for 2003, representing an increase ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
